Immunology Market By Drug Class, By Diseases Indication, By Distribution Channel, Geography and Forecast – 2021to 2026

$3,850.00$5,850.00

Published on: June 8, 2021
Clear
SKU: GMS-3199-1-1-1-1-1 Category:

OVERVIEW

1 INTRODUCTION

1.1 STUDY OBJECTIVES

• To forecast the market in terms of value, volume, and CAGR (2021-2026).

• To provide in-depth information pertaining to opportunities, risks, drivers, challenges and emerging trends in the market.

• To analyze the sector with respect to prospects, trends and market-influencing factors.

• To analyze emerging developments, including with respect to new products, partnerships, collaborations, mergers, expansions in the market.

• To provide insight into key players in the market and strategically analyze their market contribution with respect to revenue generation and competencies.

1.2 DEFINITION

1.3 STUDY SCOPE

1.3.1 MARKETS COVERED

This report includes the demand- and supply-side analyses of the Immunology Market. The supply-side market segmentation includes Drug Class, Diseases Indication, and Distribution Channel, while the demand-side segmentation includes various industries and regions.

The following diagram provides an overview of the micro markets covered in the Immunology Market report.

Figure 1 IMMUNOLOGY MARKET SEGMENTATION

Description: Amid the COVID-19, during the forecast period of 2021 to 2026, the global Immunology Market is estimated to develop at a CAGR of around 7.8%. The global Immunology Market is expected to grow in the coming years, owing to the rising demand for immunology pharmaceuticals, which is a result of the rising frequency of immunological illnesses. Due to the extreme severity of immunological illnesses, there is a growing global awareness.

Immunology Market By Drug Class, By Diseases Indication, By Distribution Channel, Geography and Forecast - 2021to 2026 1

1.3.2 GEOGRAPHIC SCOPE

Immunology Market By Drug Class, By Diseases Indication, By Distribution Channel, Geography and Forecast - 2021to 2026 2

1.3.3 YEARS CONSIDERED

Immunology Market By Drug Class, By Diseases Indication, By Distribution Channel, Geography and Forecast - 2021to 2026 3

1.4 CURRENCY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA

This section of the report helps in understanding the methodology implemented during the development of the Immunology Market report. There are 2 basic sources of information, which include secondary sources and primary sources that have been used to identify and collect the information for an extensive technical and commercial study of the Immunology Market. Secondary sources include company websites, magazines, and databases (OneSource, Factiva, and Bloomberg). Primary sources mainly include several industry experts from the core and related industries, along with preferred suppliers, manufacturers, distributors, service providers, reimbursement providers, technology developers, alliances, and standards and certification organizations related to various parts of this industry’s value chain.

The key players in the Immunology Market have been identified through secondary research, and their market share has been determined through primary and secondary research. This research includes the study of annual reports of market players to identify the top players and interview with key opinion leaders such as CEOs, directors, and marketing personnel. The following illustration depicts the market research methodology applied in making this report on the Immunology Market.

Figure 2 IMMUNOLOGY MARKET: RESEARCH DESIGN

Immunology Market By Drug Class, By Diseases Indication, By Distribution Channel, Geography and Forecast - 2021to 2026 4

2.1.1 SECONDARY DATA

In the secondary research process, various secondary sources have been referred to for identifying and collecting information important for this study. Secondary sources include corporate filings (such as annual reports, investor presentations, and financial statements); trade, business, and professional associations; white papers, related journals and certified publications; articles from recognized authors, gold and silver standard websites; directories; and databases.

Secondary research has been mainly used to obtain key information about the industry’s supply chain, market’s value chain, total pool of key players, market classification and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments from both market- and technology-oriented perspectives. The secondary data has been collected and analyzed to arrive at the overall market size, which has been further validated by primary research.

2.1.1.1 SECONDARY SOURCES

Immunology Market By Drug Class, By Diseases Indication, By Distribution Channel, Geography and Forecast - 2021to 2026 5

2.1.2 PRIMARY DATA

In the primary research process, various primary sources from both supply and demand sides have been interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives from major companies and organizations operating in the Immunology Market.

After the complete market engineering (which includes calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research has been conducted to gather information and verify and validate the critical numbers arrived at. Primary research has been conducted to identify segmentation types, industry trends, key players, competitive landscape, and key market dynamics, namely, drivers, restraints, opportunities, challenges, and industry trends, along with key strategies adopted by market players.

Extensive primary research has been conducted after acquiring knowledge about the Immunology Market
scenario through secondary research. Several primary interviews have been conducted with market experts from both the demand and supply sides across the 4 major regions—North America, Europe, Asia Pacific (APAC), and Rest of the World (RoW). RoW comprises the Middle East, Africa, and South America. Approximately, 60% and 40% primary interviews have been conducted with both the demand- and supply-side parties, respectively. This primary data has been collected through questionnaires, emails, and telephonic interviews.

2.1.2.1 PRIMARY SOURCES

Immunology Market By Drug Class, By Diseases Indication, By Distribution Channel, Geography and Forecast - 2021to 2026 6

2.1.2.2 BREAKDOWN OF PRIMARIES

Immunology Market By Drug Class, By Diseases Indication, By Distribution Channel, Geography and Forecast - 2021to 2026 7

2.2 MARKET SIZE ESTIMATION

In the complete market engineering process, both top-down and bottom-up approaches, along with several data triangulation methods, have been used to perform the market size estimation and forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and quantitative analyses have been performed on the complete market engineering process to list the key information/insights throughout the report.

The following table explains the process flow of the market size estimation.

Figure 3 Research Flow of Market Size Estimation

Immunology Market By Drug Class, By Diseases Indication, By Distribution Channel, Geography and Forecast - 2021to 2026 8

The key players in the market have been identified through secondary research, and their market shares in respective regions have been determined through primary and secondary research. This entire procedure includes the study of annual and financial reports of top players as well as extensive interviews of industry experts (such as CEOs, VPs, directors, and marketing executives) for key insights (both quantitative and qualitative) on the Immunology Market. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources. All the possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. This data has been consolidated and supplemented with detailed inputs and analysis from Global Market Studies and presented in this report.

2.2.1 BOTTOM-UP APPROACH

The bottom-up procedure has been employed to arrive at the overall size of the Immunology Market from
revenues of key players (companies) and their share in the market. The overall market size has been calculated on the basis of the revenues of the key companies identified in the market.

Figure 4 Market Size Estimation Methodology: Bottom-Up Approach

Immunology Market By Drug Class, By Diseases Indication, By Distribution Channel, Geography and Forecast - 2021to 2026 9

2.2.2 TOP-DOWN APPROACH

In the top-down approach, the overall market size has been used to estimate the size of the individual markets (mentioned in the market segmentation) through percentage splits from secondary and primary researches. For the calculation of specific market segments, the most appropriate parent market size has been used to implement the top-down approach. The bottom-up approach has also been implemented for the data extracted from the secondary research to validate the market size of various segments.

The market share of each company has been estimated to verify the revenue shares used earlier in the bottom-up approach. With the data triangulation procedure and validation of data through primaries, the overall parent market size and each individual market size have been determined and confirmed in this study. The data triangulation procedure used in this study is explained in the next section.

Figure 5 Market Size Estimation Methodology: Top-Down Approach

Immunology Market By Drug Class, By Diseases Indication, By Distribution Channel, Geography and Forecast - 2021to 2026 10

2.2.3 MARKET SHARE ESTIMATION

The market share of manufacturing companies has been arrived at on the basis of the secondary data available through paid and unpaid sources, as well as on the basis of the analysis of product portfolios of major companies and rating them according to the performance and quality. This data has been further validated through primary sources.

2.3 MARKET BREAKDOWN AND DATA TRIANGULATION

After arriving at the overall market size from the market size estimation process explained in the earlier section, the overall Immunology Market has been split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, the data triangulation and market breakdown procedures have been employed, wherever applicable. The data has been triangulated by studying various factors and trends from both the demand and supply sides. Along with this, the market has been validated using both top-down and bottom-up approaches.

Immunology Market By Drug Class, By Diseases Indication, By Distribution Channel, Geography and Forecast - 2021to 2026 11

2.4 RESEARCH ASSUMPTIONS

The following assumptions have been taken into consideration to complete the overall market engineering of the Immunology Market.

Figure7 Assumptions of Research Study

Immunology Market By Drug Class, By Diseases Indication, By Distribution Channel, Geography and Forecast - 2021to 2026 12

3 EXECUTIVE SUMMARY

FIGURE 8 MARKET GEOGRAPHICAL ANALYSIS, 2020 & 2026

Immunology Market By Drug Class, By Diseases Indication, By Distribution Channel, Geography and Forecast - 2021to 2026 13

FIGURE 9 GLOBAL IMMUNOLOGY MARKET, BY SEGMENT (2020 VS 2026)

Immunology Market By Drug Class, By Diseases Indication, By Distribution Channel, Geography and Forecast - 2021to 2026 14

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 16
1.1 STUDYOBJECTIVES 16
1.2 DEFINITION 16
1.3 STUDYSCOPE 17
1.3.1 MARKETSCOVERED 17
1.3.2 GEOGRAPHICSCOPE 18
1.3.3 YEARSCONSIDERED 18
1.4 CURRENCY 18
1.5 LIMITATIONS 19
2 RESEARCHMETHODOLOGY 20
2.1 RESEARCHDATA 20
2.1.1 SECONDARY DATA 21
2.1.1.1 SECONDARYSOURCES 21
2.1.2 PRIMARYDATA 21
2.1.2.1 PRIMARYSOURCES 22
2.1.2.2 BREAKDOWNOFPRIMARIES 23
2.2 MARKETSIZEESTIMATION 23
2.2.1 BOTTOM-UPAPPROACH 24
2.2.2 TOP-DOWNAPPROACH 25
2.2.3 MARKETSHAREESTIMATION 25
2.3 MARKET BREAKDOWN ANDDATATRIANGULATION 26
2.4 RESEARCHASSUMPTIONS 27
3 EXECUTIVESUMMARY 28
4 MARKETOVERVIEW 37
4.1 INTRODUCTION 37
4.2 MARKETDYNAMICS 37
4.2.1 DRIVERS 38
4.2.2 RESTRAINTS 40
4.2.3 OPPORTUNITIES 40
4.2.4 CHALLENGES 42
5 INDUSTRYTRENDS 44
5.1 INTRODUCTION 44
5.2 VALUECHAIN 44
6 IMMUNOLOGY MARKET, BY DRUG CLASS 48
6.1 INTRODUCTION 49
6.2 Monoclonal antibody (mAb)
6.3 Immunosuppressant
6.4 Fusion Proteins
6.5 Polyclonal antibody (pAb)
6.6 Other
7 IMMUNOLOGY MARKET, BY DISEASES INDICATION 56
7.1 INTRODUCTION 57
7.2 Rheumatoid Arthritis
7.3 Psoriatic Arthritis
7.4 Plaque Psoriasis
7.5 Prophylaxis of Organ Rejection
7.6 Inflammatory Bowel Disease
7.7 Others
8 IMMUNOLOGY MARKET, BYDISTRIBUTION CHANNEL 67
8.1 INTRODUCTION 68
8.2 Hospital
8.3 Retail
8.4 Online
9 GEOGRAPHIC ANALYSIS 111
9.1 INTRODUCTION 112
9.2 NORTHAMERICA 113
11.2.1 US 115
11.2.2 CANADA 117
11.2.3 MEXICO 118
9.3 EUROPE 120
11.3.1 UK 123
11.2.4 GERMANY 124
11.2.5 FRANCE 125
11.2.6 ITALY 126
11.2.7 RESTOFEUROPE 127
11.3 ASIAPACIFIC 127
11.4.1 CHINA 130
11.4.2 JAPAN 131
11.4.3 SOUTHKOREA 132
11.4.4 INDIA 133
11.4.5 RESTOFAPAC 134
11.5 REST OF THEWORLD(ROW) 135
11.5.1 MIDDLEEAST 136
11.5.2 SOUTHAMERICA 137
11.5.3 AFRICA 137
10 MARKET ENTROPY 139
12.1 NEW PRODUCT LAUNCHES 139
12.2 M&A’s, COLLABORATIONS, JVs, AND PARTNERSHIPS 140
11 COMPANYPROFILES 148
11.1 INTRODUCTION 148
(Business overview, Products offered, Recent developments)*
11.2 KEYPLAYERS 149
11.2.1 Janssen Global Service,LLC (Johnson & Johnson)
11.2.2 F. Hoffmann-La Roche Ltd
11.2.3 Bristol-Myers Squibb Company
11.2.4 UCB SA
11.2.5 Abbvie Inc.
11.2.6 Amgen Inc.
11.2.7 Pfizer Inc.
11.2.8 Novartis AG
11.2.9 Merck Sharp & Dohme Corp.
11.2.10 ALLERGAN
11.2.11 Company 11 & More
*Details on Business overview, Products offered, Recent developments might not be captured in case of unlisted companies.
12 APPENDIX 182
12.1 SOURCES 182
12.2 ABBREVIATIONS 185